A Weight Loss Drug Is Disrupting More Industries Than AI
Here''s a stat that should make every investor pay attention: Goldman Sachs estimates that GLP-1 weight loss drugs (Ozempic, Wegovy, Mounjaro) will be used by 30 million Americans by 2028, generating $100B+ in annual revenue.
But the real story isn''t the drug revenue. It''s the second-order effects rippling through a $2 trillion ecosystem of industries built on the assumption that Americans would stay overweight.
The Losers
- Snack food companies: Ozempic users report 30-40% reduction in snack consumption. Mondelez (MDLZ), PepsiCo (PEP), and Hershey (HSY) are already seeing softening demand in internal surveys.
- Bariatric surgery: Procedures down 25% since 2023. Why get surgery when a weekly injection works?
- Diabetes supply companies: If fewer people are obese, fewer people develop Type 2 diabetes. Dexcom (DXCM), Insulet (PODD), and glucose monitor companies face long-term headwinds.
- Fast food: McDonald''s reported its first same-store traffic decline since 2020 in Q4 2025. Ozempic suppresses cravings for exactly the kind of food fast-food chains sell.
The Winners
- Novo Nordisk (NVO) and Eli Lilly (LLY): The obvious plays. Combined market cap exceeds $1.3 trillion. Revenue growing 40%+.
- Airlines: Lighter passengers = less fuel per flight. United Airlines estimated GLP-1 drugs could save $80M/year in fuel costs by 2030.
- Activewear: People losing weight buy new clothes. Lululemon (LULU) and Nike (NKE) are seeing increased demand in smaller sizes.
- Fitness industry: Counter-intuitive, but Ozempic users exercise MORE, not less. Planet Fitness (PLNT) membership is up 12% in GLP-1 user demographics.
Investment Strategy
Long LLY and NVO for the drug revenue. Short snack food (inversely correlated). Long LULU and PLNT for the fitness renaissance. This is a decade-long trend, not a trade.
